

ImmunoPrecise Antibodies Ltd

I ? . Ž ((f \$ L & \$ + - , - ' \$, %
 B 5 . Ž % * (* , - * ' \$ *)
 5 I . Ž * % & ' - & , \$ \$ + \$ \$
 UWjcb4 dfcUWij Y]bj Ygrcfq"Vta

15:23 20 Feb 2020

ImmunoPrecise Antibodies joins global fight against coronavirus

Canadian firm ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) is joining in the fight against the deadly coronavirus.

The company announced its commitment to developing innovative vaccines against the coronavirus as well as virus-neutralizing antibodies, it said in a release Thursday.

ImmunoPrecise, which is focused on antibody discovery, will address both prophylactic and therapeutic measures to fight the virus and its associated disease, COVID-19, according to a statement.

READ: ImmunoPrecise Antibodies bolsters its capability at European operations with automated DNA printer

The Victoria, British Columbia-based firm said its Rapid Research and Development team is leveraging its "unique ability" to quickly tackle the global pandemic crisis, which has claimed over 2,100 lives so far.

Over 74,000 people around the world are currently diagnosed with the coronavirus strain.

ImmunoPrecise said it has designated Dr Ilse Roodink, the chair of IPA's subsidiary Talem Therapeutic's scientific committee, as the Coronavirus Global Project Leader. Under Roodink's supervision, the firm is organizing a global response and properly designed campaign.

ImmunoPrecise and Talem will join forces to use the sophisticated infrastructure to significantly contribute to a rapid-yet-sensible response initiated by the design and production of relevant SARS-CoV-2 target antigens, it told investors. The move will facilitate the upcoming identification of prophylactic and therapeutic compounds using ImmunoPrecise's proprietary discovery platforms, such as B Cell Select and DeepDisplay, and Talem's access to the leading transgenic animal platform OmniAb to generate human antibodies.

READ: Co-Diagnostics shares surge on report of sales of Coronavirus screening test

"We believe that ImmunoPrecise will make an impressive contribution to the global fight against SARS-CoV-2," stated Dr Jennifer Bath, ImmunoPrecise's CEO.

"With the aid of iterative advancements rapidly compiling from across the globe, including data such as the February 19 release of the prefusion form of the new coronavirus spike glycoprotein, research teams are advancing the collective effort toward the development of efficacious vaccines, therapeutic antibodies, and diagnostics. We grow more determined each day about contributing to this endeavor, as we monitor the rapid, global spread of SARS-CoV-2."

Shares of ImmunoPrecise were halted on Thursday afternoon following the news.

Price: 19.11

Market Cap: \$322.16 m

1 Year Share Price Graph



January 2020 July 2020 January 2021

Share Information

Code: IPA

Listing: TSX-V

52 week High Low
26.25 2.75

Sector: Pharma & Biotech

Website: immunoprecise.com

Company Synopsis:

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

action@proactiveinvestors.com

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).